$AMST
Amesite Inc. Stock $amst

$amst Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-Q Financial Statement

#000121390023039842 Filed on May 15, 2023

Income Statement

Concept	2023 Q1	2022 Q1
Revenue	$204.6K	$209.5K
YoY Change	-2.35%	4.76%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$870.7K	$2.422M
YoY Change	-64.05%	-3.9%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$163.3K	$240.2K
YoY Change	-32.02%	20.11%
% of Gross Profit
Operating Expenses	$1.150M	$2.422M
YoY Change	-52.51%	-3.9%
Operating Profit	-$945.5K	-$2.212M
YoY Change	-57.26%
Interest Expense	$17.48K	-$3.840K
YoY Change	-555.21%
% of Operating Profit
Other Income/Expense, Net	$816.00
YoY Change
Pretax Income	-$928.0K	-$2.216M
YoY Change	-58.12%	-4.48%
Income Tax
% Of Pretax Income
Net Earnings	-$928.0K	-$2.216M
YoY Change	-58.12%	-4.48%
Net Earnings / Revenue	-453.59%	-1057.71%
Basic Earnings Per Share	-$0.37	-$1.12
Diluted Earnings Per Share	-$0.37	-$93.10K
COMMON SHARES
Basic Shares Outstanding	30.40M shares	1.984M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.129M	$8.905M
YoY Change	-31.18%	-26.52%
Cash & Equivalents	$6.129M	$8.905M
Short-Term Investments
Other Short-Term Assets	$174.0K	$564.7K
YoY Change	-69.19%	-10.37%
Inventory
Prepaid Expenses
Receivables	$43.75K	$10.80K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$6.346M	$9.481M
YoY Change	-33.06%	-25.64%
LONG-TERM ASSETS
Property, Plant & Equipment	$73.73K	$91.15K
YoY Change	-19.11%	-8.85%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$922.0K	$1.295M
YoY Change	-28.81%	-11.3%
TOTAL ASSETS
Total Short-Term Assets	$6.346M	$9.481M
Total Long-Term Assets	$922.0K	$1.295M
Total Assets	$7.268M	$10.78M
YoY Change	-32.55%	-24.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$94.49K	$412.9K
YoY Change	-77.12%	87.69%
Accrued Expenses	$110.7K	$206.7K
YoY Change	-46.45%	-23.44%
Deferred Revenue	$106.0K	$219.2K
YoY Change	-51.65%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$311.2K	$838.8K
YoY Change	-62.9%	-18.56%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$311.2K	$838.8K
Total Long-Term Liabilities	$0.00	$0.00
Total Liabilities	$311.2K	$838.8K
YoY Change	-62.9%	-18.56%
SHAREHOLDERS EQUITY
Retained Earnings	-$32.48M
YoY Change
Common Stock	$255.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.957M	$9.937M
YoY Change
Total Liabilities & Shareholders Equity	$7.268M	$10.78M
YoY Change	-32.55%	-24.17%

Cashflow Statement

Concept	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$928.0K	-$2.216M
YoY Change	-58.12%	-4.48%
Depreciation, Depletion And Amortization	$163.3K	$240.2K
YoY Change	-32.02%	20.11%
Cash From Operating Activities	-$746.9K	-$1.276M
YoY Change	-41.46%	-4.78%
INVESTING ACTIVITIES
Capital Expenditures	$115.7K	-$78.96K
YoY Change	-246.52%	-64.11%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$115.7K	-$78.96K
YoY Change	46.52%	-64.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$2.510M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	2.510M
YoY Change	-100.0%
NET CHANGE
Cash From Operating Activities	-746.9K	-1.276M
Cash From Investing Activities	-115.7K	-78.96K
Cash From Financing Activities	0.000	2.510M
Net Change In Cash	-862.6K	1.155M
YoY Change	-174.71%	-174.02%
FREE CASH FLOW
Cash From Operating Activities	-$746.9K	-$1.276M
Capital Expenditures	$115.7K	-$78.96K
Free Cash Flow	-$862.6K	-$1.197M
YoY Change	-27.93%	6.87%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.31
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.12
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39553
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3431718
	dei	Entity Address Address Line1 EntityAddressAddressLine1	607 Shelby Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 700 PMB 214
	dei	Entity Address City Or Town EntityAddressCityOrTown	Detroit
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MI
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	48226
	dei	City Area Code CityAreaCode	(734)
	dei	Local Phone Number LocalPhoneNumber	876-8130
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001
	dei	Trading Symbol TradingSymbol	AMST
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2545440	shares
CY2023Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	6128610	usd
CY2022Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	7155367	usd
CY2023Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	43750	usd
CY2022Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	14545	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	173996	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	560084	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	6346356	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	7729996	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	73733	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	87190	usd
CY2023Q1	amst	Capitalized Software Net CapitalizedSoftwareNet	848265	usd
CY2022Q2	amst	Capitalized Software Net CapitalizedSoftwareNet	1066674	usd
CY2023Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	921998	usd
CY2022Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	1153864	usd
CY2023Q1	us-gaap	Assets Assets	7268354	usd
CY2022Q2	us-gaap	Assets Assets	8883860	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	94491	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	122285	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	81200	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	174056	usd
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	105980	usd
CY2022Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	342672	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	29500	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	109095	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	311171	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	748108	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2542440	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2542440	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2166124	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2166124	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	255	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	217	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	39438763	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	37412551	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-32481835	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-29277016	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	6957183	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	8135752	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7268354	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8883860	usd
CY2023Q1	us-gaap	Revenues Revenues	204589	usd
CY2022Q1	us-gaap	Revenues Revenues	209518	usd
	us-gaap	Revenues Revenues	722010	usd
	us-gaap	Revenues Revenues	539383	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	653128	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1239153	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1945796	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3926901	usd
CY2023Q1	amst	Technology And Content Development TechnologyAndContentDevelopment	279411	usd
CY2022Q1	amst	Technology And Content Development TechnologyAndContentDevelopment	899951	usd
	amst	Technology And Content Development TechnologyAndContentDevelopment	1191273	usd
	amst	Technology And Content Development TechnologyAndContentDevelopment	2377077	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	217528	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	282684	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	824669	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1153944	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	1150067	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	2421788	usd
	us-gaap	Operating Expenses OperatingExpenses	3961738	usd
	us-gaap	Operating Expenses OperatingExpenses	7457922	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-945478	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2212270	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3239728	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6918539	usd
CY2023Q1	us-gaap	Other Noncash Income OtherNoncashIncome	18297	usd
CY2022Q1	us-gaap	Other Noncash Income OtherNoncashIncome	1207	usd
	us-gaap	Other Noncash Income OtherNoncashIncome	36256	usd
	us-gaap	Other Noncash Income OtherNoncashIncome	8742	usd
CY2023Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	816	usd
CY2022Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	5049	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	1347	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	6711	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	17481	usd
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-3842	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	34909	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	2031	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-927997	usd
CY2021Q3	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	389085	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	11106018	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-2322239	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2216112	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3204819	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6916507	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.12
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.31
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.8
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2528845	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1983572	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2445845	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1818724	shares
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	11735090	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-2378157	usd
CY2021Q3	amst	Net Of Offering Costs NetOfOfferingCosts	140000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1360000	usd
CY2021Q4	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	22698	usd
CY2021Q4	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	422526	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	9229003	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2216111	usd
	amst	Net Of Offering Costs NetOfOfferingCosts	250450	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2509550	usd
	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	414746	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	8135752	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1577338	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	61250	usd
CY2022Q3	amst	Net Of Offering Costs NetOfOfferingCosts	142500	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1850501	usd
CY2022Q3	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	175779	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	8645944	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-699484	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	10690	usd
CY2022Q4	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	-77900	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7879250	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-927997	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	usd
CY2023Q1	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	5930	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	6957183	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3204819	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6916507	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	525631	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	682068	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	103809	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1226357	usd
	amst	Value Of Common Stock Issued In Exchange For Consulting Services ValueOfCommonStockIssuedInExchangeForConsultingServices	71940	usd
	amst	Value Of Common Stock Issued In Exchange For Consulting Services ValueOfCommonStockIssuedInExchangeForConsultingServices	22698	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-29205	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	40325	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-386086	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	265295	usd
	amst	Acquisition Of Capitalized Software Included In Accounts Payable AcquisitionOfCapitalizedSoftwareIncludedInAccountsPayable	-27794	usd
	amst	Acquisition Of Capitalized Software Included In Accounts Payable AcquisitionOfCapitalizedSoftwareIncludedInAccountsPayable	297621	usd
	amst	Accrued Compensation AccruedCompensation	-92856	usd
	amst	Accrued Compensation AccruedCompensation	-19612	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-236692	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-114010	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-79595	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-42465	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2583495	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5088820	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5554	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14267	usd
	us-gaap	Payments For Software PaymentsForSoftware	288209	usd
	us-gaap	Payments For Software PaymentsForSoftware	574123	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-293763	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-588390	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1850501	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3869550	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1026757	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1807660	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7155367	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10713091	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6128610	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8905431	usd
	amst	Acquisition Of Capitalized Software Included In Accounts Payable And Accrued Liabilities AcquisitionOfCapitalizedSoftwareIncludedInAccountsPayableAndAccruedLiabilities	70924	usd
	amst	Issuance Of Common Stock In Exchange For Consulting Services IssuanceOfCommonStockInExchangeForConsultingServices	22698	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Use of Estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i> </i></b></span></p>
CY2023Q1	us-gaap	Interest Bearing Deposits In Banks InterestBearingDepositsInBanks	250000	usd
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	722000	usd
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	539000	usd
	us-gaap	Cost Of Services Catering CostOfServicesCatering	125000	usd
	us-gaap	Cost Of Services Catering CostOfServicesCatering	49400	usd
	amst	Number Of Customers NumberOfCustomers	3	pure
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.70	pure
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	507000	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	658000	usd
CY2023Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	157000	usd
CY2022Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	234000	usd
CY2023Q1	us-gaap	Accumulated Amortization Of Other Deferred Costs AccumulatedAmortizationOfOtherDeferredCosts	2690000	usd
CY2022Q1	us-gaap	Accumulated Amortization Of Other Deferred Costs AccumulatedAmortizationOfOtherDeferredCosts	1996000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	342672	usd
CY2021Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	333200	usd
	amst	Billings Billings	487564	usd
	amst	Billings Billings	425445	usd
	amst	Less Revenue Recognized From Continuing Operations LessRevenueRecognizedFromContinuingOperations	-724256	usd
	amst	Less Revenue Recognized From Continuing Operations LessRevenueRecognizedFromContinuingOperations	-539455	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	105980	usd
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	219190	usd
	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	264043	usd
	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	539455	usd
CY2023Q1	amst	Potentially Dilutives PotentiallyDilutives	379545	shares
CY2022Q2	amst	Potentially Dilutives PotentiallyDilutives	382077	shares
	amst	Stock Warrants Issued StockWarrantsIssued	P5Y
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Risks and Uncertainties </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company operates in an industry subject to rapid change. The Company’s operations will be subject to significant risk and uncertainties including financial, operational, technological, and other risks associated with an early-stage company, including the potential risk of business failure.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On March 11, 2020, the World Health Organization declared the outbreak of a respiratory disease caused by a novel coronavirus as a “pandemic.” First identified in late 2019 and known now as COVID-19, the outbreak has impacted thousands of individuals worldwide. In response, many countries, including the United States, have implemented measures to combat the outbreak which have impacted global business operations. While management believes the Company’s operations have not been significantly impacted, the Company continues to monitor the situation. In addition, while the Company’s results of operations, cash flows and financial condition could be negatively impacted, the extent of the impact cannot be reasonably estimated at this time.</span></p>
	amst	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grants ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrants	383333	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P9Y11M19D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.022	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9298	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	263599	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	22.68
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M2D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1092	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.75
	amst	Weighted Average Remaining Contractual Termin Years Granted WeightedAverageRemainingContractualTerminYearsGranted	P10Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	7505	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	15.07
	amst	Weighted Average Remaining Contractual Termin Years Cancelled WeightedAverageRemainingContractualTerminYearsCancelled	P6Y11M23D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	257186	shares
CY2023Q1	us-gaap	Share Price SharePrice	3
CY2023Q1	us-gaap	Labor And Related Expense LaborAndRelatedExpense	6930	usd
CY2022Q1	us-gaap	Labor And Related Expense LaborAndRelatedExpense	414746	usd
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	104809	usd
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	1226357	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	305500	usd
	amst	Stock Option Grants StockOptionGrants	175500	usd
	us-gaap	Dividends Share Based Compensation Cash DividendsShareBasedCompensationCash	53625	usd
	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	124570	usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	132562	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	118478	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	118478	shares
	amst	Share Based Grants ShareBasedGrants	14084	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	132562	shares
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	30800000	usd
	amst	Operating Leases Expense Net OperatingLeasesExpenseNet	17000	usd
	dei	Entity Registrant Name EntityRegistrantName	Amesite Inc.
	amst	Acquisition Of Capitalized Software Included In Accounts Payable And Accrued Liabilities AcquisitionOfCapitalizedSoftwareIncludedInAccountsPayableAndAccruedLiabilities		usd
	amst	Issuance Of Common Stock In Exchange For Consulting Services IssuanceOfCommonStockInExchangeForConsultingServices		usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001807166

Files In Submission

Name	View Source	Status
amst-20230331_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
0001213900-23-039842-index-headers.html	Edgar Link	pending
0001213900-23-039842-index.html	Edgar Link	pending
0001213900-23-039842.txt	Edgar Link	pending
0001213900-23-039842-xbrl.zip	Edgar Link	pending
amst-20230331.xsd	Edgar Link	pending
f10q0323ex31-1_amesite.htm	Edgar Link	pending
f10q0323ex31-2_amesite.htm	Edgar Link	pending
f10q0323ex32-1_amesite.htm	Edgar Link	pending
f10q0323ex32-2_amesite.htm	Edgar Link	pending
f10q0323_amesite.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
amst-20230331_def.xml	Edgar Link	unprocessable
amst-20230331_pre.xml	Edgar Link	unprocessable
amst-20230331_lab.xml	Edgar Link	unprocessable
f10q0323_amesite_htm.xml	Edgar Link	completed
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AMST
Amesite Inc. Stock $amst

2023 Q1 Form 10-Q Financial Statement

#000121390023039842 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMST Amesite Inc. Stock $amst

2023 Q1 Form 10-Q Financial Statement

#000121390023039842 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMST
Amesite Inc. Stock $amst